Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Adenocarcinoma
|
168 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1.000 | 1 | 2017 | 2017 | ||||
Adenocarcinoma Of Esophagus
|
81 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||
Breast Carcinoma
|
2793 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
cervical cancer
|
268 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Cervix carcinoma
|
283 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Colorectal Carcinoma
|
1962 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1 | 2015 | 2015 | |||||
Gallbladder Carcinoma
|
75 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1.000 | 1 | 2013 | 2013 | ||||
Malignant neoplasm of breast
|
3417 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Malignant tumor of cervix
|
245 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Mucosal atrophy
|
5 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||
Secondary malignant neoplasm of lymph node
|
188 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1.000 | 1 | 2016 | 2016 | ||||
Squamous cell carcinoma of esophagus
|
329 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.010 | 1.000 | 1 | 2014 | 2014 | ||||
Gastric ulcer
|
7 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.020 | 1.000 | 2 | 2015 | 2019 | ||||
Intestinal metaplasia
|
24 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.020 | 1.000 | 2 | 2013 | 2016 | ||||
Malignant Neoplasms
|
1641 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.020 | 1.000 | 2 | 2015 | 2017 | ||||
Primary malignant neoplasm
|
1374 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.020 | 1.000 | 2 | 2015 | 2017 | ||||
Neoplasms
|
1644 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.030 | 0.667 | 3 | 2013 | 2014 | ||||
Carcinogenesis
|
355 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.040 | 1.000 | 4 | 2010 | 2015 | ||||
Gastritis
|
21 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.050 | 1.000 | 5 | 2014 | 2019 | ||||
Malignant neoplasm of stomach
|
615 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.100 | 0.968 | 31 | 2009 | 2019 | ||||
Bladder Neoplasm
|
281 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.100 | 1.000 | 11 | 2009 | 2019 | ||||
Nasopharyngeal carcinoma
|
320 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.700 | 1.000 | 1 | 2010 | 2010 | ||||
Gastric Adenocarcinoma
|
235 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.710 | 1.000 | 2 | 2015 | 2015 | ||||
Gastritis, Atrophic
|
61 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.720 | 1.000 | 3 | 2013 | 2019 | ||||
Stomach Carcinoma
|
652 | 0.672 | 0.320 | 8 | 142680513 | 5 prime UTR variant | C/T | snv | 0.46 | 0.45 | 0.800 | 0.971 | 34 | 2009 | 2019 |